IRIDEX (IRIX) Projected to Announce Earnings on Tuesday

IRIDEX (NASDAQ:IRIX) is projected to release its Q3 2026 results after the market closes on Tuesday, November 17th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $12.64 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 5:00 PM ET.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million.

IRIDEX Trading Up 7.4%

IRIX stock opened at $0.71 on Tuesday. The stock has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $1.02. IRIDEX has a 1 year low of $0.61 and a 1 year high of $1.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, IRIDEX currently has a consensus rating of “Hold” and an average price target of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops, manufactures and sells laser-based medical systems and disposable devices used in ophthalmic procedures. Its technologies are designed to help eye-care professionals treat glaucoma, retinal diseases and other conditions affecting vision.

The company’s product portfolio includes the Cyclo Glaucoma Laser System, which uses MicroPulse and continuous-wave laser technology for glaucoma treatment, as well as laser systems such as the IRIDEX IQ series for retinal and photocoagulation procedures.